Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist

J. Salameh, P. Bossuyt, T. McGrath, B. Thombs, Christopher J. Hyde, P. Macaskill, J. Deeks, M. Leeflang et al.

British medical journal, 2020

687 citations

Abstract

Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision making process in evidence based medicine. Although such studies are regarded as high level evidence, these reviews are not always reported completely and transparently. Suboptimal reporting of DTA systematic reviews compromises their validity and generalisability, and subsequently their value to key stakeholders. An extension of the PRISMA (preferred reporting items for systematic review and meta-analysis) statement was recently developed to improve the reporting quality of DTA systematic reviews. The PRISMA-DTA statement has 27 items, of which eight are unmodified from the original PRISMA statement. This article provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• DOI
• PubMed
• Free full text
• Publisher page

Related studies

• Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics Expert Opinion on Drug Discovery, 2019
• Challenges in Chagas Disease Drug Development Molecules, 2020
• T Cell Specificity: A Great Challenge in Chagas Disease Frontiers in Immunology, 2021
• Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice PLoS Pathogens, 2023
• Rapid Molecular Detection of Terbinafine-resistant Dermatophytes Medical Mycology Journal, 2021
• Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach Expert Opinion on Drug Discovery, 2022

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free